Live Breaking News & Updates on Prescribed Compared

Share this article
Share this article
INDIANAPOLIS, April 23, 2021 /PRNewswire/  Through clinical trial meta-analysis and real-world evidence, Eli Lilly and Company s (NYSE: LLY) Taltz
® (ixekizumab) demonstrated greater success in key measured treatment outcomes compared to other biologics in adults with moderate to severe plaque psoriasis. In the first one-year network meta-analysis based on area under the curve, Taltz showed numerically greater cumulative benefits on completely clear skin over one year compared to seven other biologics, as measured by Psoriasis Area Severity Index (PASI) 100. In three real-world analyses of U.S. claims data ranging from one to three years, patients treated with Taltz stayed on treatment longer, were more adherent to the prescription and had more days on monotherapy compared to the other biologics studied. These results are being presented virtually at the American Academy of Dermatology s Virtual Meeting Experience (AAD VMX), Apr ....

United States , Kevin Hern , Markg Lebwohl , Marlo Scott , Andrew Blauvelt , Eli Lilly , Exchange Commission , American Academy Of Dermatology Virtual Meeting Experience , Oregon Medical Research Center , Icahn School Of Medicine At Mount Sinai , Psoriasis Area Severity Index , American Academy , Virtual Meeting Experience , Lotus Mallbris , Provided Patients , Longest Lasting Complete Skin Clearance , Clinical Therapeutics , Icahn School , Mount Sinai , Helped Patients Stay , Prescribed Treatment , Taltz Took Treatment , More Frequent , Prior Biologic Use Were More Likely , Continue Treatment , Prescribed Compared ,